EU probes Sanofi flu vaccine

The International — European Commission has launched a formal antitrust investigation into Sanofi, a publicly traded company, over allegations that it engaged in a misleading communication campaign. This campaign reportedly disparaged CSL Limited — CSL Limited' Fluad, a rival flu vaccine, by suggesting it had a weaker evidence base than Sanofi's Efluelda. The campaign primarily targeted healthcare professionals in Germany and France, where Sanofi is considered to hold a dominant market position. The International — European Commission is concerned that Sanofi's actions contradict findings from the European Union — European Centre for Disease Prevention and Control and national immunization advisory groups. Sanofi denies the allegations and is cooperating with the investigation, which follows unannounced inspections at its premises in September 2025.